Correspondence to letter to the editor on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease” Hye Won Lee, Seung Up Kim Clinical and Molecular Hepatology.2026; 32(2): e244. CrossRef
Background/Aims Recently, the Korean Association for the Study of the Liver (KASL) introduced a noninvasive test-based approach that uses the fibrosis-4 (FIB-4) index followed by vibration-controlled transient elastography (VCTE) to identify high-risk patients with metabolic-associated steatotic liver disease (MASLD). In this study, the KASL two-step approach was validated by assessing the risk of liver-related event (LRE) development.
Methods We retrospectively analyzed 8,131 patients with MASLD who underwent VCTE between 2012 and 2020. The index date was defined as the date of the VCTE measurement. Using the KASL two-step approach (FIB-4 index and subsequent VCTE), patients were stratified into four groups (low-, intermediate-low-, intermediate-high-, and high-risk groups). Outcomes, including LREs such as decompensation (DCC) or hepatocellular carcinoma (HCC) were evaluated.
Results During the follow-up (median 46.6 months), 86 (1.1%) patients developed LREs (39 [0.5%] with DCC and 47 [0.6%] with HCC). The KASL two-step approach classified 67.6%, 17.7%, 5.7% and 9.0% of patients in the low-, intermediate-low-, intermediate-high-, and high-risk groups, respectively. The cumulative incidences of LREs increased proportionally according to risk stratification (0.07%, 0.10%, 0.29%, and 1.51% at 3 years and 0.35%, 0.26%, 1.94% and 5.46% at 5 years). The overall accuracy in predicting LREs ranged from 67.7–99.8%. The FIB-4 index and subsequent Agile3+, Agile 4, or FibroScan aspartate aminotransferase scores showed similar predictive abilities compared to the KASL approach.
Conclusions The KASL two-step approach is an effective and practical method for risk stratification in patients with MASLD, optimizing patient care through early identification of high-risk individuals.
Citations
Citations to this article as recorded by
Correspondence to editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease” Hye Won Lee, Seung Up Kim Clinical and Molecular Hepatology.2026; 32(1): e87. CrossRef
Risk stratification of metabolic dysfunction-associated steatotic liver disease: The KASL pathway: Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease” May Xuan Goh, Xin En Goh, Jarell Jie-Rae Tan, Vincent L Chen, Yu Jun Wong Clinical and Molecular Hepatology.2026; 32(1): 429. CrossRef
Risk Stratification of Chronic Kidney Disease in Adults Using Noninvasive Fibrosis Tests Based on the American Diabetes Association Algorithm Chan‐Young Jung, Hye Won Lee, Jung Il Lee, Han Ah Lee, Seung Up Kim Diabetes, Obesity and Metabolism.2026; 28(6): 5240. CrossRef
Letter to the editor on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease” Chunyan Wang, Jun Sun, Yinyan Li Clinical and Molecular Hepatology.2026; 32(2): e146. CrossRef
Correspondence to letter to the editor on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease” Hye Won Lee, Seung Up Kim Clinical and Molecular Hepatology.2026; 32(2): e244. CrossRef
The MASLD Journey in the General Population: Linkage‐to‐Care and Patient‐Reported Uptake of Fibrosis Risk Assessment Joo Hyun Oh, Jun‐Hyuk Lee, Sang Bong Ahn, Eunjoo Kwon, Eileen L. Yoon, Hyo Young Lee, Seon Cho, Dae Won Jun Liver International.2026;[Epub] CrossRef
Rethinking first-line screening in MASLD beyond the limitations of Fibrosis-4 index: Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease” Han Ah Lee, Young Youn Cho, Hyung Joon Kim Clinical and Molecular Hepatology.2026; 32(2): 921. CrossRef
Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach Beom Kyung Kim The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Predictors of Discordance Between Controlled Attenuation Parameter and Magnetic Resonance-Proton Density Fat Fraction in Hepatic Steatosis Dong Yun Kim, Hyung-Jin Rhee, Beom Kyung Kim Clinical and Translational Gastroenterology.2026; 17(7): e01042. CrossRef
Clinical applications and advances in noninvasive prognostic assessment of metabolic dysfunction-associated steatotic liver disease Xin-Long He, Rui-Xu Yang, Jian-Gao Fan Hepatoma Research.2026;[Epub] CrossRef
Threshold‐Defined Liver Stiffness Trajectories and Liver‐Related Event Risk in Chronic Liver Disease: A Cohort Study Dong Yun Kim, Jae Seung Lee, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Liver International.2026;[Epub] CrossRef
Risk of HCC in Elderly Patients With MASLD: Proposal of an Effective Surveillance Strategy Young Eun Chon, Kyung‐Do Han, Ju Dong Yang, Ju‐Yeong Park, Hyun‐Seok Kim, Hyung Woong Lee, Tae Seop Lim, Beom Kyung Kim Journal of Gastroenterology and Hepatology.2026;[Epub] CrossRef
The risk of cardiovascular events in metabolic dysfunction–associated steatotic liver disease according to fibrosis stage and diabetes status: A cohort study Jaehong Jeong, Jung Pyo Hong, Dong Yun Kim, Jae Seung Lee, Mi Na Kim, Jeong Eun Song, Hyun Chin Cho, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Hye Won Lee, Seung Up Kim Hepatology Communications.2026;[Epub] CrossRef
Mediterranean diet, obesity, and liver steatosis: Clinical evidence and implications for gastroenterology practice Ludovico Abenavoli, Giuseppe Guido Maria Scarlata, Maria Luisa Gambardella, Anna Giulia Loricchio, Francesco Di Giovanni, Ghizlane Bendriss Best Practice & Research Clinical Gastroenterology.2026; : 102131. CrossRef
Validation of combo ichroma as a reliable concentration-based alternative for AST and ALT measurement in liver disease monitoring Minsoo Kim, Su A Kim, Jeong Min Kim, Hee Young Kim, Ho Yeong Yoon, Sung Won Park, Daegyun Park, Ji Sook Han, Ki Tae Suk Methods.2025; 243: 66. CrossRef
First
Prev
